Protectin DX promotes epithelial injury repair and inhibits fibroproliferation partly via ALX/PI3K signalling pathway

• Published in: Journal of cellular and molecular medicine 2020-12, Vol.24 (23), p.14001-14012
• Main Authors: Yang, Jing‐Xiang, Li, Ming, Hu, Xin, Lu, Jia‐Chao, Wang, Qian, Lu, Shi‐Yue, Gao, Fang, Jin, Sheng‐Wei, Zheng, Sheng‐Xing
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; Acute Lung Injury - etiology; Acute Lung Injury - metabolism; Acute Lung Injury - pathology; acute respiratory distress syndrome; Alveolar Epithelial Cells - drug effects; Alveolar Epithelial Cells - metabolism; Alveoli; Anaplastic Lymphoma Kinase - metabolism; Angiotensin II - metabolism; Animals; Apoptosis; Apoptosis - drug effects; Cell growth; Cell injury; Cell proliferation; Collagen; Cytokines - metabolism; Disease Models, Animal; Docosahexaenoic Acids - pharmacology; Epithelial cells; fibroblast proliferation; Fibroblasts; Inflammation; Inflammation Mediators; Kinases; Laboratory animals; Lavage; Lipopolysaccharides; Lipopolysaccharides - adverse effects; Lungs; Mice; Microscopy; Neutrophils; Original; Phosphatidylinositol 3-Kinases - metabolism; Proteins; Rats; Respiratory distress syndrome; Signal transduction; Trachea; transdifferentiation; Transforming growth factor-b1; Tumor necrosis factor-TNF; type II alveolar cells; Wound healing
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.16011

Acute respiratory distress syndrome/acute lung injury (ARDS/ALI) is histologically characterized by extensive alveolar barrier disruption and excessive fibroproliferation responses. Protectin DX (PDX) displays anti‐inflammatory and potent inflammation pro‐resolving actions. We sought to investigate whether PDX attenuates LPS (lipopolysaccharide)‐induced lung injury via modulating epithelial cell injury repair, apoptosis and fibroblasts activation. In vivo, PDX was administered intraperitoneally (IP) with 200 ng/per mouse after intratracheal injection of LPS, which remarkedly stimulated proliferation of type II alveolar epithelial cells (AT II cells), reduced the apoptosis of AT II cells, which attenuated lung injury induced by LPS. Moreover, primary type II alveolar cells were isolated and cultured to assess the effects of PDX on wound repair, apoptosis, proliferation and transdifferentiation in vitro. We also investigated the effects of PDX on primary rat lung fibroblast proliferation and myofibroblast differentiation. Our result suggests PDX promotes primary AT II cells wound closure by inducing the proliferation of AT II cells and reducing the apoptosis of AT II cells induced by LPS, and promotes AT II cells transdifferentiation. Furthermore, PDX inhibits transforming growth factor‐β1 (TGF‐β1) induced fibroproliferation, fibroblast collagen production and myofibroblast transformation. Furthermore, the effects of PDX on epithelial wound healing and proliferation, fibroblast proliferation and activation partly via the ALX/ PI3K signalling pathway. These data present identify a new mechanism of PDX which targets the airway epithelial cell and fibroproliferation are potential for treatment of ARDS/ALI.